ADMA Q3 2023 Earnings — ADMA Biologics, Inc. Revenue & Financial Results | Market Cap Arena

ADMAADMA Biologics, Inc.

$4B

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$67M+63.7% YoY

Gross Profit

$25M36.6% margin

Operating Income

$9M12.9% margin

Net Income

$3M3.8% margin

EPS (Diluted)

$0.01

QoQ Revenue Growth

+11.9%

Cash Flow

Operating Cash Flow

$12M

Free Cash Flow

$11M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$349M

Total Liabilities

$198M

Stockholders' Equity

$151M

Cash & Equivalents

$74M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$67M	$41M	+63.7%
Gross Profit	$25M	$10M	+155.3%
Operating Income	$9M	-$9M	+193.2%
Net Income	$3M	-$15M	+117.2%

Revenue Segments

ADMA BioManufacturing Segment

$67M99%

Plasma Collection Centers Segment

$888,0551%

Corporate Segment

$35,7080%

Geographic Segments

United States

$65M96%

International

$3M4%